Terminated PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT00089076

MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma

Phase I/II Study of Anti-CTLA-4 Monoclonal Antibody (MDX-010) in B-cell Non-Hodgkin's Lymphoma

Sponsor: National Cancer Institute (NCI)

Conditions Adult Grade III Lymphomatoid Granulomatosis B-cell Chronic Lymphocytic Leukemia Cutaneous B-cell Non-Hodgkin Lymphoma Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue Intraocular Lymphoma Nodal Marginal Zone B-cell Lymphoma Recurrent Adult Burkitt Lymphoma Recurrent Adult Diffuse Large Cell Lymphoma Recurrent Adult Diffuse Mixed Cell Lymphoma Recurrent Adult Diffuse Small Cleaved Cell Lymphoma Recurrent Adult Grade III Lymphomatoid Granulomatosis Recurrent Adult Hodgkin Lymphoma Recurrent Adult Immunoblastic Large Cell Lymphoma Recurrent Adult Lymphoblastic Lymphoma Recurrent Grade 1 Follicular Lymphoma Recurrent Grade 2 Follicular Lymphoma Recurrent Mantle Cell Lymphoma Recurrent Marginal Zone Lymphoma Refractory Hairy Cell Leukemia Small Intestine Lymphoma Splenic Marginal Zone Lymphoma Testicular Lymphoma Waldenström Macroglobulinemia

Interventions ipilimumab laboratory biomarker analysis

Updated 6 times since 2017 Last updated: May 22, 2014 Started: Jun 30, 2004 Primary completion: Jul 31, 2008 Completion: Oct 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

Other terminated trials from National Cancer Institute (NCI)

See all terminations from National Cancer Institute (NCI)

Other Adult Grade III Lymphomatoid Granulomatosis trials with similar outcome

Browse all Adult Grade III Lymphomatoid Granulomatosis trials

This PHASE1/PHASE2 trial investigates Adult Grade III Lymphomatoid Granulomatosis and B-cell Chronic Lymphocytic Leukemia and is currently terminated or withdrawn. National Cancer Institute (NCI) leads this study, which shows 6 recorded versions since 2004 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE1_PHASE2
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE1_PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Terminated PHASE1_PHASE2

First recorded

Jun 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Rochester, United States